“The Company features alongside The Prime Minister, The Rt Hon Theresa May MP, and a small number of outstanding organisations in the Technology edition”
Arecor Ltd, the leading formulation technology company, focussed on developing superior biopharmaceuticals to improve the treatment of diabetes and other conditions, is pleased to report that it has been selected to appear in the 2016/17 edition of The Parliamentary Review.
Established by former minister, The Rt Hon David Curry shortly after the 2010 general election, The Parliamentary Review’s September release has become a key fixture in the political calendar, demonstrating how sector leaders have responded to challenges in the political and economic environment.
Following a Foreword by The Prime Minister, The Rt Hon Theresa May MP, The Parliamentary Review combines political commentary from leading journalists, with specific insight from Secretaries of State, Ministers and MPs and is an indispensable guide to industry best practice. Arecor has been selected as an example of an outstanding organisation and growth company to be featured in the Technology edition. The edition showcases best practice and acts as a learning tool to the public and private sector and is aimed particularly at leading policymakers and executives within the Technology Sector.
Dr Sarah Howell, Chief Executive of Arecor, commented:
“We at Arecor are thrilled to have been chosen to feature in this year’s Review alongside such an august and select group of companies. Our inclusion is a very welcome endorsement of the Company and of its vision to build a global diabetes specialty pharmaceutical company and leveraging its proprietary technology to develop superior products that will make a significant contribution in improving the treatment of diabetes and other conditions”.
The Parliamentary Review covers topics from biotechnology, artificial intelligence to virtual reality and the emergence of cryptocurrencies and with input from leading organisations, the Review demonstrates the critical role Britain has to play in the world’s technological future.
The Review will be sent to over 500,000 leading business executives and policy makers and the articles in the Review act as both a blueprint for success and as a template for reform.
An e-copy of The 2017 Parliamentary Review and the technology edition can be viewed via the following link:
(The profile on Arecor can be found on pages. 54-56):
*** ENDS ***
For more information, please contact:
Arecor Limited www.arecor.com
Dr Sarah Howell, Chief Executive Tel: +44 (0) 1223 426 060
Peckwater PR email@example.com
Tarquin Edwards Tel: +44 (0) 7879 458 364
Arecor Ltd is a leader in developing superior biopharmaceuticals through the application of an innovative formulation technology platform. Arecor is currently leveraging this platform to develop a portfolio of proprietary products that will enable improved treatments for diabetes via the innovative reformulation of approved proteins and peptides. Arecor's product portfolio also includes:
• Stable aqueous glucagon for emergency and artificial pancreas use,
• Novel insulin formulations to deliver ultra-rapid acting insulin analogs and;
• Ultra-concentrated rapid acting insulin to enable the miniaturisation of devices.
In addition to its internal product portfolio, Arecor partners with leading pharmaceutical and biotech companies to deliver superior reformulations of their proprietary products, which would otherwise not be possible using conventional formulation science.